Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

BriaPro Therapeutics at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

BriaPro Therapeutics brings 3 presentations to SITC 2026 in Phoenix. Its program centres on checkpoint inhibitors aimed at the tumor and on engineered forms of the immune protein CD80. It describes a soluble CD80 drug and CD80 variants redesigned to bind PD-L1 more tightly without stronger binding to CD28.

Organization	SITC 2026 Attendance
BT BriaPro Therapeutics West Vancouver, Canada
	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Tumor-targeted checkpoint inhibitors for reactivation of tumor-infiltrating lymphocytes Exhibition Halls 4-6 · Poster 405 New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment Exhibition Halls 4-6 · Poster 404 New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Molecular design of CD80 variants with increased affinity for PD-L1 and wild-type or lower affinity for CD28 Exhibition Halls 4-6 · Poster 406 New agents

Organization

SITC 2026 Attendance

BriaPro Therapeutics

West Vancouver, Canada

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Tumor-targeted checkpoint inhibitors for reactivation of tumor-infiltrating lymphocytes

Exhibition Halls 4-6 · Poster 405

New agents

Poster

Sat Nov 7
12:30–1:30pm
6:40–8:10pm

Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment